Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency - Yen, W-C; Fischer, M M; Axelrod, F (Clinical Cancer Research, 2015)
et al.